Comparing Definium Therapeutics (NASDAQ:DFTX) & ProtoKinetix (OTCMKTS:PKTX)

Definium Therapeutics (NASDAQ:DFTX) and ProtoKinetix (OTCMKTS:PKTX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends.

Profitability

This table compares Definium Therapeutics and ProtoKinetix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-100.30%	-69.22%
ProtoKinetix	N/A	N/A	N/A

Institutional & Insider Ownership

27.9% of Definium Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of ProtoKinetix shares are owned by institutional investors. 2.4% of Definium Therapeutics shares are owned by insiders. Comparatively, 0.9% of ProtoKinetix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Definium Therapeutics and ProtoKinetix”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79 million	($2.49)	-17.00
ProtoKinetix	N/A	N/A	N/A	($0.00)	-3.36

Definium Therapeutics is trading at a lower price-to-earnings ratio than ProtoKinetix, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Definium Therapeutics and ProtoKinetix, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1	0	15	2	3.00
ProtoKinetix	0	0	0	0	0.00

Definium Therapeutics presently has a consensus price target of $54.85, indicating a potential upside of 29.60%. Given Definium Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Definium Therapeutics is more favorable than ProtoKinetix.

Summary

Definium Therapeutics beats ProtoKinetix on 6 of the 10 factors compared between the two stocks.

About Definium Therapeutics

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

About ProtoKinetix

ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company's AFGPs have commercial applications primarily in health care solutions, including ophthalmology, dermatology, transplants, and biomanufacturing. It has a collaboration research agreement with the University of British Columbia. The company was formerly known as RJV Network, Inc. and changed its name to ProtoKinetix, Incorporated in July 2003. ProtoKinetix, Incorporated was incorporated in 1999 and is based in Dalton, Ohio.